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ABSTRACT
Purpose: To identify baseline prognostic factors for survival in patients with disease 
progression, during or after chemotherapy for the treatment of advanced gastric or 
gastroesophageal junction (GEJ) cancer.
Materials and Methods: We pooled data from patients randomized between 2009 and 2012 
in 2 phase III, global double-blind studies of ramucirumab for the treatment of advanced 
gastric or GEJ adenocarcinoma following disease progression on first-line platinum- and/
or fluoropyrimidine-containing therapy (REGARD and RAINBOW). Forty-one key baseline 
clinical and laboratory factors common in both studies were examined. Model building 
started with covariate screening using univariate Cox models (significance level=0.05). 
A stepwise multivariable Cox model identified the final prognostic factors (entry+exit 
significance level=0.01). Cox models were stratified by treatment and geographic region. The 
process was repeated to identify baseline prognostic quality of life (QoL) parameters.
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Results: Of 1,020 randomized patients, 953 (93%) patients without any missing covariates 
were included in the analysis. We identified 12 independent prognostic factors of poor 
survival: 1) peritoneal metastases; 2) Eastern Cooperative Oncology Group (ECOG) 
performance score 1; 3) the presence of a primary tumor; 4) time to progression since prior 
therapy <6 months; 5) poor/unknown tumor differentiation; abnormally low blood levels 
of 6) albumin, 7) sodium, and/or 8) lymphocytes; and abnormally high blood levels of 9) 
neutrophils, 10) aspartate aminotransferase (AST), 11) alkaline phosphatase (ALP), and/or 12) 
lactate dehydrogenase (LDH). Factors were used to devise a 4-tier prognostic index (median 
overall survival [OS] by risk [months]: high=3.4, moderate=6.4, medium=9.9, and low=14.5; 
Harrell's C-index=0.66; 95% confidence interval [CI], 0.64–0.68). Addition of QoL to the 
model identified patient-reported appetite loss as an independent prognostic factor.
Conclusions: The identified prognostic factors and the reported prognostic index may help 
clinical decision-making, patient stratification, and planning of future clinical studies.
Keywords: Prognosis; Stomach neoplasms; Gastroesophageal junction; Survival
INTRODUCTION
Gastric cancer is the fifth most common malignancy worldwide, representing 6.8% of all new 
cancers [1-3], and the third leading cause, accounting for 8.8%, of all cancer-related deaths. 
The 5-year survival rate declines rapidly with the extent of the cancer, from 65.4% for patients 
with localized lesions to 29.9% for those with regional metastases, decreasing further to 
4.5% for those with distant metastases [3]. Owing to the generally asymptomatic nature in 
the early stages of gastric cancer, up to two-thirds of patients present with regional or distal 
metastatic disease [4-6].
Surgical resection is the primary treatment for non-metastatic gastric cancer, and several 
studies have suggested prognostic indices for these patients. However, patients with metastatic 
disease are treated with systemic chemotherapy, with few studies aimed at determining 
prognostic indices for these populations. The Royal Marsden Hospital [7,8] proposed 
a prognostic index from 4 factors associated with poor prognosis in first-line therapy: 
performance status (PS) ≥2, liver metastasis, peritoneal metastasis, and elevated alkaline 
phosphatase (ALP). This analysis was performed using data exclusively from Western centers, 
although the index was validated in 2 independent datasets in Korea [9] and Japan [10]. 
Takahari and colleagues [10], noting that there are “substantial differences” in the prognosis 
of Asian and Western patients with advanced gastric cancer, proposed a prognostic index for 
first-line chemotherapy based on 4 similar risk factors: PS ≥1, number of metastatic sites ≥2, 
no prior gastrectomy, and elevated ALP [10]. However, this secondary analysis was performed 
exclusively with an Asian population [10]. There is a paucity of prognostic data after first-line 
chemotherapy in gastric cancer patients. Catalano and colleagues [11], and more recently, 
Kanagavel and colleagues [12], proposed prognostic indices to identify low-, intermediate-, and 
high-risk groups of patients with metastatic gastric cancer receiving second-line chemotherapy. 
However, both studies were limited by small sample sizes (n=175 and n=126, respectively) and a 
retrospective, non-randomized study design.
In contrast to other cancer types, such as non-Hodgkin lymphoma, multiple myeloma, 
and cancers of the breast, kidney, prostate, or colon, no common prognostic index exists 
for advanced gastric cancer, in part due to the limited numbers of studies performed, low 
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patient numbers, or limited geographic reach. Development of a generally applicable 
prognostic index for advanced gastric cancer would be valuable for assessing survival 
prognosis of individual patients, aiding in stratification for new randomized clinical trials 
(RCTs), and guiding decisions for optimal treatment strategies [7,8,10,12-14].
Improvement in quality of life (QoL), even in the absence of prolonged survival time, is an 
important outcome that should be considered when recommending second-line therapy [13]. 
Evaluation of QoL includes physical, psychological, and social dimensions, and best reflects 
how patients perceive their own state of health [7,15]. Chau and colleagues [7] found that 
a higher baseline QoL was associated with improved survival with first-line chemotherapy, 
indicating that QoL reflects a patient's overall well-being and has prognostic value.
The present analysis was undertaken using 2 large RCTs with Western and Asian 
populations to devise a prognostic index for survival in patients with previously treated 
advanced gastric/gastroesophageal junction (GEJ) cancer. A secondary analysis that 
considered baseline QoL was also performed.
MATERIALS AND METHODS
Patient data were obtained from 2 large global RCTs of second-line therapy for advanced 
gastric/GEJ cancer that included patients from Asia, Europe, North and South America, 
Australia, and Africa. For the REGARD study (NCT00917384), 355 patients were randomized 
between October 2009 and January 2012 in 29 countries to receive either ramucirumab 
(Cyramza®; Eli Lilly and Company, Indianapolis, IN, USA) (8 mg/kg; n=238) or placebo 
(n=117), intravenously once every 2 weeks plus best supportive care [16]. The RAINBOW 
study (NCT01170663) was conducted with 665 patients who were randomized between 
December 2010 and September 2012 [17] to receive either ramucirumab (8 mg/kg, n=330) or 
placebo (n=335), intravenously on days 1 and 15, plus paclitaxel (Taxol®; Bristol-Myers Squibb 
Company, Princeton, NJ, USA) (80 mg/m²) intravenously on days 1, 8, and 15 of a 28-day 
cycle. The study designs and consolidated standards of reporting trials diagrams have been 
previously published [16,17].
Patient selection
Both studies had similar eligibility criteria. Patients had advanced gastric/GEJ 
adenocarcinoma and disease progression within 4 months of first-line chemotherapy 
(platinum and/or fluoropyrimidine with or without an anthracycline). Patients had an Eastern 
Cooperative Oncology Group (ECOG) PS of 0 or 1, and measurable or non-measurable 
evaluable disease [16,17] as defined by response evaluation criteria in solid tumors (RECIST) 
version 1.1 (RAINBOW) or version 1.0 (REGARD) [18]. Both studies assessed QoL using the 
European Organization for Research and Treatment of Cancer (EORTC) 30-item Quality of 
Life Core Questionnaire (QLQ-C30) version 3.0 [19]. The individual data from the REGARD 
and RAINBOW studies were pooled (1,020 patients, 794 deaths), providing the largest to date 
second-line gastric cancer population to be analyzed for prognostic factors.
Both studies were conducted in accordance with the ethical principles originating in the 
Declaration of Helsinki, good clinical practices, and all applicable laws and regulations. 
The Institutional Review Board at each site approved the study, and all subjects provided 
written informed consent before undergoing any study procedure.
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Statistical analysis
The endpoint for the present analysis was overall survival (OS), defined as the time from 
randomization to time of death from any cause, with patients censored at the last-known-
alive date if they were not known to have died at the time of the data cut-off.
Given the large sample size of the pooled studies (1,020 patients, 794 events), the model 
can accommodate a large number of covariates. A covariate pool was generated from all 
41 baseline factors common in both studies (18 clinical characteristics, 22 laboratory 
parameters, and geographic region). The clinical characteristics included: age, race, 
ethnicity, sex, weight loss, ECOG PS, body weight, disease progression during first-line 
therapy or within 4 months, time since diagnosis, histologic subtype, presence of liver 
metastases, disease measurability, number of metastatic sites, primary tumor location, 
presence of primary tumor, time to progression since prior therapy, tumor differentiation, 
and presence of peritoneal metastasis. The laboratory parameters included: levels of alanine 
aminotransferase (ALT), ALP, aspartate aminotransferase (AST), lactate dehydrogenase 
(LDH), albumin, bilirubin, creatinine, erythrocytes, hematocrit, hemoglobin, leucocytes, 
lymphocytes, neutrophils, platelets, phosphate, potassium, magnesium, sodium, and 
calcium; prothrombin international normalized ratio (INR); prothrombin time (PT); and 
activated partial thromboplastin time (PTT).
Continuous variables for clinical characteristics were dichotomized using thresholds 
specified in the study protocols (age, weight loss, time to progression since prior therapy, 
and number of metastatic sites) or using the median (body weight and time since diagnosis) 
(Table 1). Laboratory parameters were analyzed based on local laboratory assessments with 
3 categories (abnormally high, normal, and abnormally low). The categorized laboratory 
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Table 1. Clinical factors: baseline summary and univariate analysis
Clinical factors Patient characteristics Univariate Cox model
No. of patients Poor prognostic group, 
No. of patients in each group (%)
HR P-value
Peritoneal metastases (yes vs. no) 1,020 424 (41.6) 1.617 <0.0001
ECOG PS (1 vs. 0) 1,020 661 (64.8) 1.611 <0.0001
No. of metastatic sites (≥3 vs. 0 to 2) 1,020 345 (33.8) 1.445 <0.0001
Weight loss within 3 mo (≥10% vs. <10%) 1,018 154 (15.1) 1.544 <0.0001
Time since diagnosis (<9 mo vs. ≥9 mo) 1,020 524 (51.4) 1.353 <0.0001
Presence of a primary tumor (yes vs. no) 1,020 678 (66.5) 1.360 <0.0001
Time to progression since prior therapy (<6 mo vs. ≥6 mo) 1,016 645 (63.5) 1.346 <0.0001
Tumor differentiation (poor/unknown vs. well/moderate) 1,020 643 (63.0) 1.344 <0.0001
Body weight (<60 kg vs. ≥60 kg) 1,019 433 (42.5) 1.284 0.0014
Histologic subtype (diffuse vs. intestinal) 1,020 388 (38.0) 1.239 0.0119
Histologic subtype (other* vs. intestinal) 1,020 265 (26.0) 1.160 0.1181
Age group (<65 yr vs. ≥65 yr) 1,020 643 (63.0) 1.151 0.0613
Liver metastases (yes vs. no) 1,020 448 (43.9) 1.139 0.0727
Disease progression (during first-line therapy vs. within 4 mo after the last 
dose of first-line therapy)
979 475 (48.5) 1.176 0.0746
Sex (female vs. male) 1,020 300 (29.4) 1.142 0.0936
Ethnicity (Hispanic or Latino vs. not Hispanic or Latino) 1,020 117 (11.5) 1.251 0.1755
Race (other† vs. Caucasian) 1,020 54 (5.3) 1.140 0.4453
Race (Asian vs. Caucasian) 1,020 287 (28.1) 1.174 0.4493
Measureable disease (no vs. yes) 1,019 174 (17.1) 1.042 0.6756
Primary tumor location (GEJ vs. gastric junction) 1,020 228 (22.4) 1.023 0.7977
The factors that were included in the final model are shown in bold text. For each factor, the poor prognostic group is shown first for each group pair within parentheses. 
HR = hazard ratio; ECOG = Eastern Cooperative Oncology Group; PS = performance status; GEJ = gastroesophageal junction. 
* Histologic subtype (other) means mixed and unknown/missing; †Race (other) includes African-American, American Indian, or Alaska Native, multiple race,  
and others.
values were used in the analysis to account for measurement variability across local 
laboratories.
Two factors needed special handling: treatment and geographic region. Treatment has 
substantial impact on OS, as significant treatment benefits were demonstrated in both studies. 
As discussed in the introduction, geographic region is a well-known prognostic factor in gastric 
cancer, which is also confirmed in this pooled data. As these 2 factors are not individual patient 
characteristics, they were adjusted in Cox models as stratification factors instead of covariates. 
Effects of selected covariates were very similar if these 2 factors were controlled as covariates 
(small change in hazard ratio [HR] estimates: maximum=−0.09, average=−0.02).
Prognostic factors were identified using Cox models in 2 steps. First, univariate Cox models 
(including each individual factor as the sole covariate) screened the covariates (significance 
level=0.05). Then, the final prognostic factors were identified based on a multivariable 
Cox model that was built using stepwise selection of covariates (entry and exit significance 
level=0.01). This stringent significance level (0.01) was used to reduce the impact of 
multiplicity due to the large number of covariates, which decreases the chance of identifying 
false positive factors as prognostic. Once the factors were identified, HRs with 99% 
confidence limits were estimated for each prognostic factor based on the final Cox model 
with only the selected factors as covariates (to reduce the number of patients who may have 
been excluded due to missing values of unselected factors). Based on the relative magnitude 
of each factor’s effect on OS (i.e., HR), a prognostic index was devised and grouped into 4 
levels: low, medium, moderate, and high risk.
The discriminatory performance of the prognostic index was calculated using Harrell's 
C-index [20] and assessed visually using Kaplan-Meier plots. The internal validation was 
assessed via bootstrapping to estimate over-fitting optimism from model building.
To identify any additional independent prognostic factors from the QoL data, we repeated 
the above analyses with the 15 scales from the QLQ-C30. Following the EORTC scoring 
guidelines [21], each scale is reported as 0 to 100, with higher scores on the global health 
status and functioning scales, and lower scores on the symptom scales representing better 
QoL. For this analysis, these scores were dichotomized by median value (or 0 vs. >0 if 
median=0, or 100 vs. <100 if median=100). Once the univariate Cox models identified the 
significant QoL parameters (significance level=0.05), these parameters were included in the 
multivariable stepwise Cox regression, while the previously selected clinical and laboratory 
factors were forcibly included in the model (to identify additional prognostic value from QoL 
data). Once the QoL factors were selected, final estimates of coefficients were based on the 
model with only the selected clinical, laboratory, and QoL factors, to maximize the number 
of patients included in the analysis.
RESULTS
Of the 1,020 total patients included in the RAINBOW and REGARD studies, 953 (93%) were 
included in the final multivariable Cox regression analysis for this study, after excluding 
patients with missing covariate values. A significant number of this population included 
patients with peritoneal metastasis (41.6%), ECOG PS 1 (64.8%), time to progression 
since prior therapy <6 months (63.5%), metastatic sites ≥3 (33.8%), poorly differentiated 
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tumors (63%), and diffuse tumor subtype (38%) (Table 1), which suggests this analysis 
included many critically ill patients. The Kaplan-Meier survival curve based on data pooled 
from both studies showed a median OS of 6.9 months, 12-month survival rate of 29% (95% 
confidence interval [CI], 26.1–32.0), and 24-month survival rate of 9.1% (95% CI, 6.8–11.8) 
(Supplementary Fig. 1). Results of the univariate analyses for clinical characteristics are 
summarized in Table 1, and for laboratory parameters in Table 2. It is important to note 
that the target populations for the RAINBOW and REGARD studies were very similar. The 
multivariable stepwise Cox regression with clinical and laboratory parameters identified 12 
factors associated with poor prognosis for OS (Table 3): presence of peritoneal metastases, 
ECOG PS of 1, presence of a primary tumor, time to progression since prior therapy <6 
months, poor/unknown tumor differentiation, abnormally low blood levels of albumin, 
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Table 2. Laboratory parameters: baseline summary and univariate analysis
Laboratory parameters No. of patients  
included in 
the analysis
Low vs. normal or high High vs. normal or low
Low, No. of patients 
in each group (%)
HR P-value High, No. of patients 
in each group (%)
HR P-value
Albumin 997 324 (32.5) 1.811 <0.0001 8 (0.8) 0.485 0.1083
Sodium 1,008 149 (14.8) 2.645 <0.0001 14 (1.4) 0.614 0.1786
Hematocrit 1,010 760 (75.3) 1.487 <0.0001 2 (0.2) 5.563 0.0172
Hemoglobin 1,010 781 (77.3) 1.376 0.0003 2 (0.2) 5.563 0.0172
Erythrocytes 1,007 754 (74.9) 1.365 0.0004 8 (0.8) 1.422 0.4353
Lymphocytes 1,007 262 (26.0) 1.263 0.0004 9 (0.9) 0.574 0.2183
Neutrophils 1,010 42 (4.2) 0.573 0.0056 166 (16.4) 2.121 <0.0001
Potassium 1,007 46 (4.6) 1.567 0.0072 32 (3.2) 1.287 0.2322
Creatinine 1,008 132 (13.1) 1.211 0.0733 103 (10.2) 1.146 0.2445
AST 1,009 15 (1.5) 0.541 0.0897 205 (20.3) 1.583 <0.0001
Calcium 986 137 (13.9) 1.192 0.1036 32 (3.3) 1.076 0.7376
Phosphate 964 53 (5.5) 0.776 0.1280 62 (6.4) 0.936 0.6803
ALP 994 6 (0.6) 0.410 0.1290 392 (39.4) 1.506 <0.0001
Activated PPT 970 91 (9.4) 1.208 0.1330 63 (6.5) 1.125 0.4445
Magnesium 979 125 (12.8) 1.110 0.3429 26 (2.7) 1.000 1.0000
LDH 982 44 (4.5) 0.853 0.3766 317 (32.3) 1.455 <0.0001
PT 749 42 (5.6) 0.868 0.4617 147 (19.6) 0.925 0.4883
Prothrombin INR 995 63 (6.3) 0.900 0.4856 93 (9.4) 1.432 0.0045
Leukocytes 1,010 72 (7.1) 0.907 0.4949 141 (14.0) 1.983 <0.0001
Platelets 1,010 124 (12.3) 1.074 0.5142 98 (9.7) 1.279 0.0445
Bilirubin 1,009 14 (1.4) 0.882 0.6961 47 (4.7) 1.183 0.3378
ALT 1,009 36 (3.6) 1.071 0.7174 95 (9.4) 1.266 0.0452
The factors that were included in the final model are shown in bold text. 
HR = hazard ratio; AST = aspartate aminotransferase; ALP = alkaline phosphatase; PTT = partial thromboplastin time; LDH = lactate dehydrogenase; PT = 
prothrombin time; INR = international normalized ratio; ALT = alanine aminotransferase.
Table 3. Multivariable Cox regression analysis of the OS for prognostic factors in advanced gastric cancer
Prognostic factors of poor survival HR (99% CI) for mortality P-value
Presence of a primary tumor 1.31 (1.05–1.62) 0.0014
Poor/unknown tumor differentiation 1.33 (1.08–1.64) 0.0005
Time to progression since prior therapy <6 mo 1.35 (1.10–1.66) 0.0002
ECOG PS 1 1.39 (1.12–1.73) 0.0001
Presence of peritoneal metastases 1.49 (1.22–1.83) <0.0001
High ALP level 1.28 (1.03–1.60) 0.0030
Low lymphocyte level 1.31 (1.05–1.63) 0.0015
High LDH level 1.31 (1.05–1.63) 0.0019
Low albumin level 1.33 (1.07–1.65) 0.0006
High AST level 1.37 (1.06–1.76) 0.0014
High neutrophil level 1.52 (1.17–1.99) <0.0001
Low sodium level 2.04 (1.54–2.71) <0.0001
OS = overall survival; HR = hazard ratio; CI = confidence interval; ECOG = Eastern Cooperative Oncology Group; PS = 
performance status; ALP = alkaline phosphatase; LDH = lactate dehydrogenase; AST = aspartate aminotransferase.
sodium, and/or lymphocytes (below the institutional normal range), and abnormally high 
blood levels of neutrophils, AST, ALP, and/or LDH (above the institutional normal range).
A prognostic score can be created using patient-level linear prediction (xbeta). Since the risks 
(as measured by HRs) of these factors had a similar magnitude (except low sodium), it was 
possible to create a simpler prognostic score without losing too much information for each 
patient by counting the number of prognostic factors (thus regarding their impact as equal, 
except low sodium, which was counted twice due to its relative size of HR being the square of 
others). Accordingly, the prognostic score ranged from 0 to 13, and approximately followed a 
normal distribution (Fig. 1).
A prognostic index was then devised using prognostic scores as follows: “Low”= 0–2, 
“Medium”=3–4, “Moderate”=5–6, and “High”=7–13 (Table 4). Kaplan-Meier survival curves 
were generated for each of these 4 indices (Fig. 2), and a clear survival curve-separation 
was seen for the 4 risk groups (P<0.0001). The median OS values for the high-, moderate-, 
medium-, and low-risk groups were 3.4, 6.4, 9.9, and 14.5 months (Fig. 2), respectively. 
Discriminatory performance of the prognostic index had a Harrell's C-index of 0.66 (95% 
CI, 0.64–0.68). The over-fitting optimism due to model building was 0.01, as assessed by 
mean optimism of 200 bootstrapping samples, which suggested very little over-fitting of 
the model.
Thirteen of the 15 QoL scales were significant in the univariate analyses (Supplementary 
Table 1). However, when included with the 12-selected clinical and laboratory factors, 
only patient-reported appetite loss was an independent prognostic factor (P<0.0001, 
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Fig. 1. Histogram of prognostic scores among the 953 patients. The distribution approximates a Gaussian 
distribution.
Table 4. Prognostic index (No. of patients in each group=953)
Index Score Total No. of included patients (%)
Low 0–2 107 (11.2)
Medium 3–4 322 (33.8)
Moderate 5–6 310 (32.5)
High 7–13 214 (22.5)
Supplementary Table 2). The HRs of each of the 12 previous factors were relatively 
unchanged by inclusion of appetite loss in the model.
DISCUSSION
To the best of our knowledge, this is the largest global RCT dataset used to date to generate 
a prognostic index for second-line gastric cancer chemotherapy. The large sample size offers 
opportunities to derive a more reliable prognostic index, which distinguishes the current 
work from prior observations, most utilizing very limited datasets. Based on individual 
patient data pooled from 1,020 patients in 2 large phase III studies (RAINBOW and 
REGARD), we identified 12 clinical and laboratory factors that predict the survival of patients 
with advanced gastric/GEJ cancer after first-line chemotherapy: peritoneal metastases, ECOG 
PS of 1, the presence of a primary tumor, time to progression since prior therapy <6 months, 
poor/unknown tumor differentiation, abnormally low blood levels of albumin, sodium, and/
or lymphocytes, and abnormally high blood levels of neutrophils, AST, ALP, and/or LDH. 
These factors were used to generate a prognostic index that divides patients into 4 risk 
groups (median OS by risk [months]: high=3.4, moderate=6.4, medium=9.9, and low=14.5), 
ranging from low to high risk of death. The discrimination power of this prognostic index, 
calculated using Harrell's C-index [20], is illustrated by the clear separation of the Kaplan-
Meier survival curves for OS, along with the large range, 3.4 months to 14.5 months, in 
median survival time and a discrimination performance as measured by Harrell's C-index of 
0.66. As the C-index is data-dependent and impacted by non-comparable patient-pairs (e.g., 
both patients with censored OS), 0.66 is comparable to that of many widely used prognostic 
systems in oncology such as the Child-Pugh system and albumin-bilirubin (ALBI) grade in 
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2 84 10 14 20 24 26 2818 22
P<0.001
At risk
Low 107 106 102 90 81 64 52 42 33 24 17 11 6 0 0
Medium 322 301 267 221 182 131 96 67 51 32 18 11 4 3 0
Moderate 310 271 213 153 112 81 57 35 24 16 12 5 3 2 0
High 214 141 82 44 22 13 8 4 2 1 0 0 0 0 0
Risk group Line color No. Event Median
Low 107 60 14.46
Medium 322 222 9.92
Moderate 310 260 6.41
High 214 200 3.35
Fig. 2. The Kaplan-Meier curves showing OS for each of the 4 risk groups determined by the prognostic factors. The median survival and the patients at risk for 
each of these groups are also presented. 
OS = overall survival.
hepatocellular carcinoma [22]. Internal validation was conducted through use of bootstrap 
validation, which revealed very little over-fitting of the model, with a mean optimism of 0.01. 
However, independent external validation of the model is warranted.
We extended the analyses by including baseline QoL data from the same studies, which 
found patient-reported appetite loss to be an additional independent prognostic factor. 
Although the clinical factor of weight-loss within the previous 3 months was prognostic in 
the univariate analyses, the subjective assessment of appetite had independent prognostic 
value. Among other disease-related symptoms and aspects of patient well-being, this 
symptom apparently has the greatest impact on OS. Although correlations existed among 
many QoL scales, only appetite loss showed significant contribution of additional power to 
predict patient's prognosis after controlling the 12-selected strong prognostic factors. All 
other scales may be prognostic to some extent (as shown in the univariate analysis), but did 
not meet statistical criteria to qualify as prognostic factors, given that 12 strong prognostic 
factors were included in the model. However, lack of standardized methods to assess 
patient-reported appetite loss in clinical practice may limit its use in a prognostic index.
Despite several attempts to develop a prognostic index for gastric cancer, little remains 
known about the prognostic factors for metastatic gastric cancer, especially in the second-
line setting. Most studies either focused on first-line therapy or gastric resection [7,10,14,23-
25]. Chau and colleagues [7] identified 4 independent prognostic factors in a large study 
(1,080 patients), but this was performed exclusively in the United Kingdom, and was 
based on first-line treatment. Three of the 4 factors (PS, peritoneal metastasis, and high 
ALP) were also identified as prognostic factors in our study. Takahari and colleagues [10] 
also identified 4 prognostic factors (PS, ALP, number of metastatic sites, and no prior 
gastrectomy) exclusively in Asian patients. Only the first 2 factors were similar to those 
reported by Chau and colleagues [7], and 3 were identified in our study. Kanagavel and 
colleagues [12] identified 3 independent prognostic factors in patients with advanced gastric 
cancer receiving second-line therapy. PS and time to disease progression after first-line 
therapy were also identified in our analyses. In addition, Kanagavel and colleagues [12] 
included hemoglobin level as a factor. However, since hemoglobin levels are readily affected 
by blood transfusion or by erythropoietin, the reliability of this factor should be interpreted 
with caution. Moreover, this study may lack sufficient power due to small sample size (126 
patients). In our study, high AST was identified as a strong prognostic factor in the univariate 
analysis (P<0.0001), although liver metastasis, which may cause an increase in AST, was not 
identified as a prognostic factor (P=0.070). This is consistent with another study [26] that 
identified AST as a prognostic factor, and suggests that serum AST could be a much stronger 
prognostic factor than liver metastasis.
Generating a generally applicable prognostic index is complicated by large variations in 
the incidence and mortality of gastric cancer globally, as well as substantial treatment 
variations in different countries. For example, gastric cancer represents only 1.3% of new 
cancers in the US, but accounts for 13% of all new cancers in China and the Western Pacific 
[2]. In addition, while only 2% of cancer-related deaths in the US are from gastric cancer, 
gastric cancer accounts for 15% and 14% of cancer-related deaths in China and the Western 
Pacific, respectively [2]. Moreover, considerable regional differences in treatment protocols 
exist [10]. It is therefore a strength of this analysis that it included not only a large number 
of patients, but also 27 (RAINBOW) and 29 (REGARD) countries from 6 continents [16,17].
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Discussions of statistical methods and limitations are addressed in detail within the 
supplementary material section (Supplementary Text 1). In addition, the results presented 
here are derived from clinical trial data of patients who had undergone selection processes. 
In general practice, patients may present with characteristics or conditions that could 
compromise the validity of the predictive models used here. Additional studies will be required 
to identify a simplified prognostic model that takes into consideration different patient 
characteristics or conditions. Furthermore, relevant clinicopathological parameters that affect 
the laboratory parameters may need to be considered for clinical application of this model.
In summary, individual responses to chemotherapy are largely variable, and many patients 
have disease progression after first-line chemotherapy [7,10,12]. Second-line chemotherapy is 
not appropriate for all patients. Therefore, prognostic factors that can be applied with a high 
degree of confidence and across geographic regions become important decision-supporting 
tools. The identification of a prognostic index will help with appropriate treatment decisions, 
as well as enhance patient stratification in RCTs to achieve robust results. Several reports 
have demonstrated the feasibility and potential use of laboratory data in the stratification 
of patients in clinical trials [27-29]. Our current study raises the importance of assessing 
novel tissue-based prognostic biomarkers for their discriminatory ability over and above the 
prognostic index identified here by easily obtainable clinicopathological parameters. The 
large variation in patient survival and widely differing prognostic profiles underscore the 
need for RCTs balancing these profiles between treatment arms to obtain unbiased estimates 
of treatment effects.
ACKNOWLEDGEMENTS
We thank all patients and institutions involved in this study. The authors also thank Michael 
Ossipov, Angela Lorio, and Jeanne Claypoole of inVentiv Health Clinical for assistance with 
writing and editorial support. Eli Lilly and Company contracted inVentiv Health Clinical for 
writing and editorial services.
SUPPLEMENTARY MATERIALS
Supplementary Text 1
Discussion of statistical methods and limitations
Click here to view
Supplementary Table 1
QoL factors (EORTC QLQ-C30): baseline summary and univariate analysis
Click here to view
Supplementary Table 2
Multivariable Cox regression analysis of OS for prognostic factors including QoL in advanced 
gastric cancer
Click here to view
141https://jgc-online.org https://doi.org/10.5230/jgc.2017.17.e16
Prognostic Factors of Gastric Cancer Survival
Supplementary Table 3
Covariates with Spearman correlation coefficient (r) >0.4
Click here to view
Supplementary Table 4
Regression analysis of the OS for prognostic factors including low sodium level, ECOG PS 1, 
and presence of peritoneal metastases
Click here to view
Supplementary Fig. 1
The Kaplan-Meier curve for the pooled patient population showing probability of OS. The 
median survival and the patients at risk are also presented.
Click here to view
REFERENCES
 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality 
worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386. 
PUBMED | CROSSREF
 2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer 
Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for 
Research on Cancer; 2013 [cited 2015 Aug 1]. Available from: http://globocan.iarc.fr.
 3. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al., eds. SEER Cancer Statistics 
Review, 1975–2012 (based on November 2014 SEER data submission, posted to the SEER web site, April 
2015) [Internet]. Bethesda (MD): National Cancer Institute; 2015 [cited 2015 Aug 1]. Available from: 
http://seer.cancer.gov/csr/1975_2012/.
 4. Avital I, Pisters PW, Kelsen DP, Willett CG. Cancer of the stomach. In: DeVita VT, Lawrence TS, 
Rosenberg SA, eds. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 9th 
ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2011;924-954.
 5. Koh TJ, Wang TC. Tumors of the stomach. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & 
Fordtran's Gastrointestinal and Liver Disease. 7th ed. Philadelphia (PA): Saunders, 2002;829-844.
 6. Layke JC, Lopez PP. Gastric cancer: diagnosis and treatment options. Am Fam Physician 2004;69:1133-1140.
PUBMED
 7. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis 
in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, 
randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-2403. 
PUBMED | CROSSREF
 8. Chau I, Ashley S, Cunningham D. Validation of the Royal Marsden hospital prognostic index in advanced 
esophagogastric cancer using individual patient data from the REAL 2 study. J Clin Oncol 2009;27:e3-e4. 
PUBMED | CROSSREF
 9. Koo DH, Ryoo BY, Kim HJ, Ryu MH, Lee SS, Moon JH, et al. A prognostic model in patients who receive 
chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous 
models. Cancer Chemother Pharmacol 2011;68:913-921. 
PUBMED | CROSSREF
 10. Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, et al. Determination of prognostic 
factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled 
trial, Japan clinical oncology group 9912. Oncologist 2014;19:358-366. 
PUBMED | CROSSREF
 11. Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, et al. Second-line chemotherapy for 
patients with advanced gastric cancer: who may benefit? Br J Cancer 2008;99:1402-1407. 
PUBMED | CROSSREF
142https://jgc-online.org https://doi.org/10.5230/jgc.2017.17.e16
Prognostic Factors of Gastric Cancer Survival
 12. Kanagavel D, Pokataev IA, Fedyanin MY, Tryakin AA, Bazin IS, Narimanov MN, et al. A prognostic 
model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol 
2010;21:1779-1785. 
PUBMED | CROSSREF
 13. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American 
Society of Clinical Oncology. J Clin Oncol 1996;14:671-679. 
PUBMED | CROSSREF
 14. Sun KY, Xu JB, Chen SL, Yuan YJ, Wu H, Peng JJ, et al. Novel immunological and nutritional-based 
prognostic index for gastric cancer. World J Gastroenterol 2015;21:5961-5971.
PUBMED
 15. Dorcaratto D, Grande L, Ramón JM, Pera M. Quality of life of patients with cancer of the oesophagus and 
stomach. Cir Esp 2011;89:635-644. 
PUBMED | CROSSREF
 16. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy 
for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an 
international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-39. 
PUBMED | CROSSREF
 17. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel 
versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal 
junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 
2014;15:1224-1235. 
PUBMED | CROSSREF
 18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation 
criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. 
PUBMED | CROSSREF
 19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization 
for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international 
clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376. 
PUBMED | CROSSREF
 20. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating 
assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387. 
PUBMED | CROSSREF
 21. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 Scoring 
Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer, 2001.
 22. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function 
in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 
2015;33:550-558. 
PUBMED | CROSSREF
 23. Kusano T, Shiraishi N, Shiroshita H, Etoh T, Inomata M, Kitano S. Poor prognosis of advanced gastric 
cancer with metastatic suprapancreatic lymph nodes. Ann Surg Oncol 2013;20:2290-2295. 
PUBMED | CROSSREF
 24. Louvet C, Carrat F, Mal F, Mabro M, Beerblock K, Vaillant JC, et al. Prognostic factor analysis in advanced 
gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP 
regimen). Cancer Invest 2003;21:14-20. 
PUBMED | CROSSREF
 25. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 
5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor 
analysis. Eur J Cancer 1994;30A:1263-1269. 
PUBMED | CROSSREF
 26. Chen SL, Xue N, Wu MT, Chen H, He X, Li JP, et al. Influence of preoperative serum aspartate 
aminotransferase (AST) level on the prognosis of patients with non-small cell lung cancer. Int J Mol Sci 
2016;17:1474-1486. 
PUBMED | CROSSREF
 27. Zhang K, Lai Y, Axelrod R, Campling B, Hyslop T, Civan J, et al. Modeling the overall survival of patients 
with advanced-stage non-small cell lung cancer using data of routine laboratory tests. Int J Cancer 
2015;136:382-391. 
PUBMED | CROSSREF
 28. Watine J, Friedberg B. Laboratory variables and stratification of metastatic colorectal cancer patients: 
recommendations for therapeutic trials and for clinical practice guidelines. Clin Chim Acta 2004;345:1-15. 
PUBMED | CROSSREF
143https://jgc-online.org https://doi.org/10.5230/jgc.2017.17.e16
Prognostic Factors of Gastric Cancer Survival
 29. Watine J, Friedberg B, Bouarioua N. Biological variables and stratification of patients with inoperable 
non-small-cell bronchial cancer: recommendations for future trials. Cancer Radiother 2002;6:209-216. 
PUBMED | CROSSREF
144https://jgc-online.org https://doi.org/10.5230/jgc.2017.17.e16
Prognostic Factors of Gastric Cancer Survival
